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Broiler type chickens were immunized intramuscularly 
with a DNA vaccine encoding hemagglutinin (HA) from 
H5N1 avian influenza virus. The chickens were divided 
into four groups: control group which was not immu-
nized, a group which obtained only one dose, and two 
groups which were immunized twice, one group with a 
boost two weeks after the priming and the other four 
weeks. Blood samples were collected at several time 
points and the dynamics of the humoral response to 
the vaccine was studied. High level of anti-HA antibod-
ies was detected only in the last two groups, that is in 
chickens immunized according to the prime-boost strat-
egy, regardless of the schedule. An additional interesting 
observation of this study was detection of the cross-re-
activity of an anti-H5 HA positive serum with H5N2 and 
H1N1 viruses, suggesting that the DNA vaccine tested 
can induce antibodies of a broad specificity.
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INTRODUCTION
Chickens are the main poultry species raised for meat, 
eggs and hobby. During the hundreds of years of breed-
ing they have been subjected to intensive selection which 
could affect their immunological characteristics and sus-
ceptibility to avian influenza, a poultry disease of great 
importance (Alexander, 2007; Graham-Rowe, 2011). 
Although the threat of an H5N1 influenza outbreak is 
now less imminent than during the 2006 epidemic, it 
is still real. Construction of an effective vaccine against 
avian influenza is a challenging task due to the continu-
ous threat of new outbreaks caused by new subtypes, 
like H7N9, which occurred recently in China (Gao et 
al., 2013b). Therefore, not only the control and surveil-
lance of the influenza virus spread is important (Capua 
& Cattoli, 2013) but there is also an unquestionable need 
for modern veterinary vaccines that could be prepared 
without handling live viruses and would be consistent 
with DIVA European strategy (differentiating infection 
in vaccinated animals). DNA vaccines can potentially 
fulfill these criteria. In most experimental DNA vac-
cines for chickens two vaccine doses are administered 
one week (Mahmood et al., 2007; Song et al., 2010) or 
two weeks (Li et al., 2003; Li et al., 2013) apart, with the 
first dose applied at various age. The studies were often 
performed with SPF (specific pathogen-free) chickens, 
most frequently Leghorn White, which is a layer type 
breed (Yang et al., 2009; Chen et al., 2011; Gao et al., 
2013a). Modern broiler lines, like Ross 508 (Mahmood 
et al., 2007; Song et al., 2013) or Chine’s Yellow Hair 
chickens, a traditional Asian meat breed (Xu et al., 2008; 
Song et al., 2010) have been used much less frequently in 
such experiments. Other breeds, like Rhode Island Red, 
were tested only sporadically (Haygreen et al., 2006). All 
of these breeds have different metabolism, life span or 
body weight. Differences in optimal vaccination proto-
cols for these lines could be thus anticipated.
The present study is part of a broader research project 
focused on chicken immunity and vaccination against 
avian influenza. The main aim of this study was on 
analysis of antigen-specific humoral response to a DNA 
vaccine encoding hemagglutinin from the H5N1 influ-
enza virus isolated in Poland from a wild swan, using 
the broiler line Ross 308 most popular in the poultry in-
dustry in Poland. The immunological response of these 
broilers to the DNA vaccine administered according to 
three different schedules was studied in order to estab-
lish an optimal vaccination program.
MATERIALS AND METHODS
DNA vaccine. Construction of the plasmid for DNA 
vaccination with inserted synthetic DNA encoding HA 
from the H5N1 A/swan/Poland/305-135V08/2006 
(EpiFluDatabase [http://platform.gisaid.org]; Accession 
No. EPI156789), vaccine preparation and chicken im-
munization were described previously (Stachyra et al., 
2014). Briefly, the HA gene was optimized to the do-
mestic chicken codon bias and engineered to contain de-
letion of the proteolytic cleavage site (from Arg-341 to 
Arg-346). Next, it was cloned into the pCI mammalian 
expression vector (Promega GmbH, Germany) under 
control of CMV promoter. A dose of 125 µg of plas-
mid DNA mixed with 20 µl of Lipofectin transfection 
reagent (Life Technologies, USA) was used for each im-
munization.
Immunizations. Broiler (Ross 308) chickens were 
housed in cages in an experimental poultry house under 
standard commercial conditions. The vaccine was ad-
ministered intramuscularly. The schedule of immuniza-
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tions and blood collections is shown in Fig. 1A. Shortly, 
broilers were divided into four groups (n=7-14): (1) B-
CNTR — control which did not receive any treatment, 
(2) B-1x-7 — immunized once on day 7, (3) B-2x-7/21 
— immunized twice on days 7 and 21, (4) B-2x-7/35 — 
immunized twice on day 7 and 35. The experiment have 
been approved by the II Local Ethical Committee for 
Animal Experiments at Medical University of Warsaw, 
permit number 17/2009. All efforts were made to mini-
mize suffering. At the end of the experiment the birds 
were humanely euthanized by decapitation.
Ezyme-linked immunosorbent assay (ELISA). In-
direct ELISA for detection of anti-HA antibodies in se-
rum was performed in 96-well polystyrene plates (MediS-
orp, Nunc, Denmark) as described previously (Stachyra 
et al., 2014). Plates were coated overnight with 50 µl of 
affinity-purified, recombinant H5 HA (17-530, Δ341-346, 
6xHis-tag at C-terminus) antigen (A/swan/Poland/305-
135V08/2006 (H5N1)) produced in a baculovirus system 
by Oxford Expression Technologies, UK, diluted in PBS 
to 6 µg/ml. Goat anti-chicken IgY (Fc specific)–HRP 
IgGs (Pierce/Thermo Scientific, IL, USA) were used as 
secondary antibodies. All sera were diluted 200-folds.
Cells and influenza viruses. Madin–Darby canine 
kidney cells (MDCK) (Collection of the Department of 
Recombinant Vaccines, University of Gdansk, Poland) 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(D-MEM) (Sigma–Aldrich, USA), supplemented with 
10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
glutamine, 0.2% bovine serum albumin, 25 mM HEPES 
buffer, 100 U/ml penicillin, 100 µg/ml streptomycin, at 
37°C under 5% CO2.
The avian influenza virus A/ostrich/Denmark/725/96 
(H5N2) (kindly provided by R. Manvell, AHVLA, Wey-
Figure 1. Dynamics of anti-H5 HA IgY level in sera of immunized chickens.
(A) Schedule of immunization. The immunization (black arrows) and blood collection (white arrows) are indicated above the respective 
day of life of the chickens from each group. (B) ELISA results for sera collected on the indicated days after hatching (21, 28, 35, 42 and 
49) calculated for group with standard errors (±SE) and standard deviations (±S.D.) indicated. Asterisks denote mean values statistically 
different from the corresponding mean in the control group (CNTR). Chickens were immunized on day 7 (B-1x-7), 7 and 21 (B-2x-7/21), or 
7 and 35 (B-2x-7/35). Number (N) of chickens per group is indicated.
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bridge, UK) and human influenza virus (isolate 32U of 
the pandemic human influenza A/H1N1 virus) from 
the collection of the Department of Recombinant Vac-
cines, University of Gdansk, Poland were propagated in 
MDCK cells in the presence of 2 µg/ml TPCK (L-1-to-
sylamide-2-phenylethyl chloromethyl ketone) — trypsin 
(Sigma-Aldrich, USA). Viral stocks were stored at –70°C 
and titrated by plaque assay before use.
Immunoperoxidase monolayer assay (IPMA). 
MDCK cell monolayers in 12-well plates were infected 
for 1 h at 37°C with either avian influenza virus A/os-
trich/Denmark/725/96 (H5N2) or isolate 32U of the 
pandemic human influenza A/H1N1 virus. Unbound vi-
ral particles were removed by washing with serum-free 
medium, and the cell monolayers were overlaid with 
fresh serum-free medium containing 1.2% Avicel (FMC 
BioPolymer, USA) and 2 µg/ml TPCK-trypsin. After 
3 days, cells were washed with phosphate-buffered sa-
line (PBS), fixed with 4% paraformaldehyde and virus-
infected cells were immunostained by incubating for 1 
h with collected sera diluted 1:8 in PBS containing 1% 
Tween 20 and 5% fetal bovine serum (FBS). Anti-chick-
en horseradish peroxidase (HRP)-conjugated antibody 
(Santa Cruz Biotechnology, USA) was used as secondary 
antibody (diluted 1:1000 in PBS containing 1% Tween 
20 and 5% FBS). Infected cells were detected using the 
Vector Nova-Red kit (Vector Laboratories Ltd., UK). 
The infected cells appeared as red plaques on unstained 
background of uninfected cells.
Statistical analysis. For comparison of ELISA results 
in different groups the ANOVA Tukey HSD (Honestly 
Significant Difference) test for unequal n was applied, 
using STATISTICA 6.0 (Statsoft, Poland). The results 
were considered significant for p < 0.05.
RESULTS AND DISCUSSION
Three groups of broiler chickens were immunized in-
tramuscularly either once or twice with 125 µg of DNA 
vaccine per dose and the level of anti-HA antibodies in 
sera of the immunized chickens was determined by the 
ELISA test at different time points. The experiments 
were performed in poultry house cages, using standard 
commercial conditions, which allowed us to observe 
natural reactions to the immunization. The study lasted 
6 weeks, which corresponds to the broiler life span in 
commodity production. The broiler chickens grow very 
fast and have intensive metabolism. Therefore, the im-
munization was started as early as possible; the first dose 
was administered on the seventh day after hatching. The 
second dose (if applied) was administered, depending on 
the group, on day 21 or 35. The ELISA test demon-
strated clear differences between the groups. The mean 
values of the levels of anti-HA antibodies in the experi-
mental groups are shown in Fig. 1B. They were higher 
in the group immunized once than in the control group, 
but the difference was statistically nonsignificant. The 
second vaccination (booster) resulted in an increased hu-
moral response regardless of the booster time. A statis-
tically significant increase of the anti-HA antibody titer 
was observed one week after the second dose in both 
groups that were immunized twice. The anti-HA level 
remained high in those groups until the end of the ex-
periment (42 or 49 days). These results indicate that two 
doses of the experimental DNA vaccine were required 
to elicit a high level of anti-HA antibodies. Interestingly, 
large biological variation was observed among respond-
ers within the experimental groups (Fig. 1B). Similar 
substantial inter-individual variation has been described 
in other DNA vaccine studies with chickens (Shan et al., 
2011), which could be related to differences in DNA up-
take by muscle fibers.
A considerable number of publications report chicken 
immunization with DNA vaccines, especially with avi-
an influenza antigens. Such studies sometimes included 
measurement of IgY humoral response in serum samples 
and analysis of its dynamics (Jalilian et al., 2010; Liniger 
et al., 2012), but most of them concentrated on hemag-
Figure 2. Cross-reactivity of the positive serum with a high anti-HA titer with two viral strains.
Chickens were immunized according to scheme B-2x-7/21 and sera collected on day 42 were used. For IPMA test, MDCK cells were mock 
infected or infected with avian influenza virus A/ostrich/Denmark/725/96 (H5N2) or isolate 32U of the pandemic human influenza A/
H1N1 virus. At 1 h post infection, unbound virus was removed and cells were incubated with overlay medium. Three days post infection 
cells were fixed and immunostained using the indicated sera (No. 141 — sample positive in ELISA test or No. 228 — negative control) to 
detect influenza A virus-infected cells. The results of IPMA test (A) and the results of ELISA test of the same samples (B) are shown.
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glutinin inhibition tests and virus neutralization assays 
(Jiang et al., 2007; Shan et al., 2011; Lim et al., 2012). In 
this study, the specificity of the anti-HA antibodies in-
duced by our experimental DNA vaccine was evaluated 
preliminarily using the IPMA test which enables detec-
tion of cells exposing HA on their surface, such as cells 
infected by the virus. Two serum samples collected at 
day 42, one from a non-immunized chicken (negative 
in ELISA, No. 228) and one from a positive individual 
with a high titer of antibodies, immunized twice on days 
7 and 21 (No. 141) were analyzed. The results clearly 
indicated that the serum negative in ELISA remained 
negative in the IPMA test, while the positive serum with 
a high anti-HA titer was able to detect cells infected by 
the H5N2 (A/ostrich/Denmark/725/96) virus (Fig. 2). 
Interestingly, the positive serum also detected cells in-
fected by a serologically distant pandemic H1N1 strain 
of human influenza A virus, which apparently indicates 
the presence of broad-specificity antibodies in the serum 
(Fig. 2). The discovered cross-reactivity and presumed 
ability of our experimental DNA vaccine to induce anti-
bodies with broad specificity is a very interesting obser-
vation justifying further detailed studies.
Acknowledgements
We thank Anna Doraczyńska-Filipczak for excellent 
veterinary support and Katarzyna Florys (IBA), Józef 
Kapusta (IBA), Katarzyna Szatraj (IBB) for their help 
and cooperation during immunization experiments and 
immunological analysis.
Acknowledgments of financial support
This work was supported by Innovative Economy 
Program, Grant No. WND-POIG.01.01.02-00-007/08.
REFERENCES
Alexander DJ (2007) An overview of the epidemiology of avian influ-
enza. Vaccine 25: 5637–5644.
Capua I, Cattoli G (2013) Prevention and control of highly pathogenic 
avian influenza with particular reference to H5N1. Virus Res 178: 
114–120.
Chen HY, Zhang HY, Li XS, Cui BA, Wang SJ, Geng JW, Li K (2011) 
Interleukin-18-mediated enhancement of the protective effect of an 
infectious laryngotracheitis virus glycoprotein B plasmid DNA vac-
cine in chickens. J Med Microbiol 60: 110–116.
Gao H, Li K, Gao L, Qi X, Gao Y, Qin L, Wang Y, Wang X (2013a) 
DNA prime-protein boost vaccination enhances protective immu-
nity against infectious bursal disease virus in chickens. Vet Microbiol 
164: 9–17.
Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu 
H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, 
Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang 
Y, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang 
S, Hao P, Yang W, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, 
Yuan Z, Shu Y (2013b) Human infection with a novel avian-origin 
influenza A (H7N9) virus. N Engl J Med 368:1888–1897.
Graham-Rowe D (2011) Epidemiology: Racing against the flu. Nature 
480: S2–S3.
Haygreen EA, Kaiser P, Burgess SC, Davison TF (2006) In ovo DNA 
immunisation followed by a recombinant fowlpox boost is fully 
protective to challenge with virulent IBDV. Vaccine 24: 4951–4961.
Jalilian B, Omar AR, Bejo MH, Alitheen NB, Rasoli M, Matsumoto 
S (2010) Development of avian influenza virus H5 DNA vaccine 
and MDP-1 gene of Mycobacterium bovis as genetic adjuvant. Genet 
Vaccines Ther 8: 4.
Jiang Y, Yu K, Zhang H, Zhang P, Li C, Tian G, Li Y, Wang X, Ge J, 
Bu Z, Chen H (2007) Enhanced protective efficacy of H5 subtype 
avian influenza DNA vaccine with codon optimized HA gene in a 
pCAGGS plasmid vector. Antiviral Res 75: 234–241.
Li J, Huang Y, Liang X, Lu M, Li L, Yu L, Deng R (2003) Plasmid 
DNA encoding antigens of infectious bursal disease viruses induce 
protective immune responses in chickens: factors influencing effi-
cacy. Virus Res 98: 63–74.
Li K, Gao H, Gao L, Qi X, Gao Y, Qin L, Wang Y, Wang X (2013) 
Adjuvant effects of interleukin-18 in DNA vaccination against in-
fectious bursal disease virus in chickens. Vaccine 31: 1799–1805.
Lim KL, Jazayeri SD, Yeap SK, Alitheen NB, Bejo MH, Ideris A, 
Omar AR (2012) Co-administration of avian influenza virus H5 
plasmid DNA with chicken IL-15 and IL-18 enhanced chickens im-
mune responses. BMC Vet Res 8: 132.
Liniger M, Summerfield A, Ruggli N (2012) MDA5 can be exploited 
as efficacious genetic adjuvant for DNA vaccination against lethal 
H5N1 influenza virus infection in chickens. PLoS One 7: e49952.
Mahmood MS, Hussain I, Siddique M, Akhtar M, Ali S (2007) DNA 
vaccination with VP2 gene of very virulent infectious bursal disease 
virus (vvIBDV) delivered by transgenic E. coli DH5alpha given 
orally confers protective immune responses in chickens. Vaccine 25: 
7629–7635.
Shan S, Jiang Y, Bu Z, Ellis T, Zeng X, Edwards J, Tian G, Li Y, Ge 
J, Chen H, Fenwick S (2011) Strategies for improving the efficacy 
of a H6 subtype avian influenza DNA vaccine in chickens. J Virol 
Methods 173: 220–226.
Song H, Qiu B, Yan R, Xu L, Song X, Li X (2013) The protective 
efficacy of chimeric SO7/IL-2 DNA vaccine against coccidiosis in 
chickens. Res Vet Sci 94: 562–567.
Song H, Song X, Xu L, Yan R, Shah MA, Li X (2010) Changes of 
cytokines and IgG antibody in chickens vaccinated with DNA vac-
cines encoding Eimeria acervulina lactate dehydrogenase. Vet Para-
sitol 173: 219–227.
Stachyra A, Góra-Sochacka A, Sawicka R, Florys K, Sączyńska V, 
Olszewska M, Pikuła A, Śmietanka K, Minta Z, Szewczyk B, Zagór-
ski W, Sirko A (2014) Highly immunogenic prime-boost DNA vac-
cination protects chickens against challenge with homologous and 
heterologous H5N1 virus. Trials Vaccinol 3: 40–46.
Xu Q, Song X, Xu L, Yan R, Shah MA, Li X (2008) Vaccination of 
chickens with a chimeric DNA vaccine encoding Eimeria tenella 
TA4 and chicken IL-2 induces protective immunity against coccidi-
osis. Vet Parasitol 156: 319–323.
Yang T, Wang HN, Wang X, Tang JN, Gao R, Li J, Guo ZC, Li 
YL (2009) Multivalent DNA vaccine enhanced protection efficacy 
against infectious bronchitis virus in chickens. J Vet Med Sci 71: 
1585–1590.
